DOCUMENT
Hauser_Ofatumumab Benefit-risk MS Infographic_revised_12June2023.pdf (183.02 kB)
VIDEO
video abstract .mp4 (86.43 MB)
1/0
The development of ofatumumab, a fully human anti-CD20 monoclonal antibody for practical use in relapsing multiple sclerosis treatment
media
posted on 2023-07-13, 09:49 authored by Adis journals on behalf of, Stephen L Hauser, Ludwig Kappos, Amit Bar-Or, Heinz Wiendl, David Paling, Mitzi Williams, Ralf Gold, Andrew Chan, Ron Milo, Ayan Das Gupta, Goeril Karlsson, Roseanne Sullivan, Gordon Graham, Martin Merschhemke, Dieter A Haering, Patrick VermerschThe article associated with this page has been accepted for online publication and is in the final stages of production. The link to the full text will be made available on this page in the next few days.
The above infographic and video abstract represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, and copyright information, please see the full text online. (see “read the peer-reviewed publication” opposite).
